



**REQUEST  
FOR  
CONTINUED EXAMINATION (RCE)  
TRANSMITTAL**

Address to:  
Commissioner for Patents  
Box RCE  
Washington, DC 20231

Application Number	09/806,925
Filing Date	Jun. 20, 2001
First Named Inventor	Araki
Art Unit	1651
Examiner Name	R. Davis
Attorney Docket Number	MTSU 1001US

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

**RECEIVED**

1. **Submission required under 37 CFR 1.114**

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on \_\_\_\_\_  
(Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☐ Other \_\_\_\_\_

DEC 17 2002

TECH CENTER 1600/2900

2. **Miscellaneous**

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other \_\_\_\_\_

3. **Fees**

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

- a. ☐ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. \_\_\_\_\_
- i. ☐ RCE fee required under 37 CFR 1.17(e)
- ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17)
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Check in the amount of \$ 740.00 enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print/Type)	Kevin J. Dunleavy	Registration No. (Attorney/Agent)	32,024
Signature	<i>Kevin J. Dunleavy</i>	Date	December 4, 2002

**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	Jane Webb	Date	December 4, 2002
Signature	<i>Jane Webb</i>		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.



DOCKET NO.: MTSU-1001US

#171  
DB  
1/6/13

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Araki et al.

Serial No.: 09/806,925

Group No.: 1651

Filed: June 20, 2001

Examiner: R. Davis

For: Preventative or Remedies for  
Infection, Anti-Endotoxin Agents,  
Vaccine Adjuvants and Growth  
Promoters

RECEIVED

DEC 17 2002

TECH CENTER 1600/2900

PRELIMINARY AMENDMENT

Commissioner for Patents  
BOX RCE  
Washington, D.C. 20231

Dear Sir:

Preliminary to the examination of the above-identified application, please amend the above-captioned patent application as follows. For the convenience of the Examiner, all the currently pending claims are attached below.

\* \* \*

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

Date: December 4, 2002

I hereby certify that this paper, along with any document or paper referred to as being attached or enclosed, is being deposited with the United States Postal Service as first class mail under 37 CFR 1.8 in an envelope addressed to the Commissioner for Patents, BOX RCE, Washington, D.C. 20231.

Lynne Webb  
Name of person mailing correspondence

Lynne Webb  
Signature of person mailing correspondence